News and Press Releases

Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024

23 May 2024 -- Tokyo, Japan -- Eisai Co announced today the presentation of research across multiple types of cancer from its oncology portfolio and pipeline during the 2024 American...

Category: Clinical Trials, Drug Discovery
Posted: May 23, 2024

4-6-10 Koishikawa, Bunkyo-ku, Tokyo 112-8088, Japan

Global oncology trial investigator sites increase by half in five years, finds new Phesi analysis

China flagged as significant contributor to growth, but poor investigator selection is causing trial failures 23 May 2024 -- Massachusetts, US -- Phesi, a leading clinical development analytics company, has...

Category: Biotechnology, Clinical Trials
Posted: May 22, 2024

East Lyme, Connecticut, US

Mission Therapeutics commences landmark trial of MTX325, a potential disease-modifying treatment for Parkinson’s Disease

Builds on preclinical proof-of-concept that MTX325 protects dopamine-producing brain cells by enhancing mitophagy – the process cells use to remove dysfunctional mitochondria 21 March 2024 -- Cambridge, UK -- Mission...

Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: May 21, 2024

Moneta (Building 280), Babraham Research Campus, Cambridge, CB22 3AT, United Kingdom

Greenphire Named 2024 “Best Overall Patient Engagement Service” by MedTech Breakthrough Awards

16 May 2024 -- Pennsylvania, US --  Greenphire, a leading innovator in software solutions for improving clinical research site performance and participant satisfaction, has received a 2024 MedTech Breakthrough Award for...

Category: Clinical Trials, Logistics
Posted: May 16, 2024

1018 W. 9th Avenue, Suite 200 King of Prussia, PA 19406

Allyx Therapeutics Announces Positive Phase 1b Multiple Ascending Dose Data and Advances ALX-001 to Patients

Safety of ALX-001 reinforced by new data presented at AD/PD 2024 Conference in Lisbon, Portugal Two oral doses selected for further study in Alzheimer’s and Parkinson’s disease patients. 11 March 2024...

Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: May 11, 2024

555 Long Wharf Drive Floor 11 New Haven, CT 06511, US

Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness Within 24 Weeks and Initial Hearing Improvements in a Second Child at Six Weeks

Preliminary data detailed in an ASGCT oral presentation include results for one of the youngest children in the world to receive a gene therapy for genetic deafness Ongoing phase 1/2...

Category: Biotechnology, Clinical Trials
Posted: May 8, 2024

The Charter Building, Vine Street, Uxbridge, Middlesex, United Kingdom, UB8 1JG

Signant Health extends eCOA leadership position through operational innovations that reduce timelines by at least one-third

8 May 2024 -- Pennsylvania, US -- Signant Health, the leader in evidence generation for modern clinical trials, announced today that it has substantially reduced implementation timelines for its flagship...

Category: Clinical Trials, Other
Posted: May 8, 2024

4000 Chemical Road Suite 300 Plymouth Meeting, PA 19462

Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024

Non-Small Cell Lung Cancer (NSCLC) Development Program Data to be Presented, Including the phase 3 EVOKE-01 Study Updated Results from phase 2 EDGE-Gastric Study of Fc-Silent Anti-TIGIT Domvanalimab Plus Anti-PD-1...

Category: Clinical Trials, Drug Discovery
Posted: May 7, 2024

2400 Broadway Santa Monica, CA 90404

Phesi launches predictive Patient Burden Score to improve trial efficiency, patient experience and investigator site performance

Latest real-world metric in Phesi’s AI-driven Trial Accelerator quantifies patient burden to unlock a patient-centric approach to trial design and implementation 7 May 2024 -- Boston, US -- Phesi, a...

Category: Clinical Trials
Posted: May 7, 2024

East Lyme, Connecticut, US

TAR-210 results show 90% recurrence-free survival and 90% complete response in patients with high-risk and intermediate-risk non-muscle-invasive bladder cancer, respectively

Updated results reinforce the potential of TAR-210 to transform treatment of non-muscle-invasive bladder cancer with fibroblast growth factor receptor (FGFR) alterations 5 May 2024 -- Beerse, Belgium -- Janssen-Cilag International,...

Category: Clinical Trials, Drug Discovery
Posted: May 5, 2024

Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG

Bespak and Medicines Evaluation Unit collaborate to accelerate clinical trials on climate-friendly inhalers

Relationship will provide pharmaceutical industry with fast route to clinical evaluation of low GWP pMDIs 3 May 2024 -- Holmes Chapel and Manchester, UK -- Bespak, a leading contract development...

Category: Clinical Trials, Drug Delivery
Posted: May 3, 2024

Osteolabs to Present New Clinical Data from Over 2,400 OsteoTest Routine Samples at the WCO-IOF-ESCEO Congress

New data fully supporting potential for OsteoTest to qualify as new universal diagnostic method for early osteoporosis risk assessment and therapeutic control 9 April 2024 -- Kiel, Germany -- Osteolabs,...

Category: Biotechnology, Drug Discovery, Pharmaceutical
Posted: April 12, 2024

5 Bisham Court Marlow SL7 1SD UK

Kite to Present Comparison of Outcomes of Tecartus (brexucabtagene autoleucel) from the Pivotal ZUMA-2 Trial Versus the EBMT Registry of alloSCT Patients in Mantle Cell Lymphoma (MCL) at 50th EBMT 2024

Additional analysis demonstrates cost-effectiveness of axicabtagene ciloleucel versus standard of care as second-line therapy In patients With large B-cell lymphoma In Italy 9 April 2024 -- Stockley Park, UK --...

Category: Biotechnology, Clinical Trials
Posted: April 12, 2024

2400 Broadway Santa Monica, CA 90404

NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumour Biology in a Paired Biopsy Clinical Study

NUC-7738 reprogrammes cancer cell lipid metabolism to make tumours less aggressive and promote cancer cell death NUC-7738 alters ribosome biogenesis and the regulation of genes critical for cancer growth and...

Category: Biotechnology, Clinical Trials, Pharmaceutical
Posted: April 10, 2024

https://www.nucana.com/

Myonex Announces Acquisition of Safeway Compounding Pharmacy to Expand its Clinical Trial Services Across the US

9 April 2024  -- Horsham, US -- Myonex, a leading global clinical trial supply company, has completed the acquisition of SaveWay Compounding Pharmacy of Newark, US. The pharmacy will operate as...

Category: Clinical Trials
Posted: April 9, 2024

100 Progress Dr., Horsham, PA 19044